These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26792297)

  • 1. Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study.
    Lodhi RJ; Masand S; Malik A; Shivakumar K; McAllister VD; O'Keane V; Young LC; Heald AH; Sherwood RA; Aitchison KJ
    Schizophr Res; 2016 Feb; 170(2-3):245-51. PubMed ID: 26792297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics.
    Hwang TJ; Lo WM; Chan HY; Lin CF; Hsieh MH; Liu CC; Liu CM; Hwu HG; Kuo CH; Chen WJ
    J Clin Psychopharmacol; 2015 Dec; 35(6):635-44. PubMed ID: 26488675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study.
    Yoon HW; Lee JS; Park SJ; Lee SK; Choi WJ; Kim TY; Hong CH; Seok JH; Park IH; Son SJ; Roh D; Kim BR; Lee BO
    Clin Neuropharmacol; 2016; 39(6):288-294. PubMed ID: 27438182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder.
    Woo YS; Bahk WM; Park YM; Chung S; Yoon BH; Won S; Lee JG; Lee HB; Kim W; Jeong JH; Lee K; Kim MD
    Int Clin Psychopharmacol; 2016 Sep; 31(5):275-86. PubMed ID: 27487259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole induced Impulse Control Disorders: Where do we stand?
    Mahapatra A; Sharma P; Sagar R
    Asian J Psychiatr; 2016 Oct; 23():128-130. PubMed ID: 27969070
    [No Abstract]   [Full Text] [Related]  

  • 7. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
    Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
    Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
    Jeong HG; Lee MS; Lee HY; Ko YH; Han C; Joe SH
    Int Clin Psychopharmacol; 2012 Jul; 27(4):177-83. PubMed ID: 22407277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in sexual dysfunction with aripiprazole: a switching or add-on study.
    Mir A; Shivakumar K; Williamson RJ; McAllister V; O'Keane V; Aitchison KJ
    J Psychopharmacol; 2008 May; 22(3):244-53. PubMed ID: 18308789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?
    Jen YW; Hwang TJ; Chan HY; Hsieh MH; Liu CC; Liu CM; Hwu HG; Kuo CH; Lin YT; Chien YL; Chen WJ
    BMC Psychiatry; 2020 Nov; 20(1):552. PubMed ID: 33228575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole-Induced Hypoprolactinemia in an Adult Male with First-Episode Psychosis.
    Propst AJ; Jarvis GE; Margolese HC
    Clin Schizophr Relat Psychoses; 2016; 9(4):173-6. PubMed ID: 25711510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new approach for evaluating bone turnover in chronic kidney disease.
    Tolouian R; Hernandez GT; Chiang WY; Gupta A
    Eur J Intern Med; 2010 Jun; 21(3):230-2. PubMed ID: 20493428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Effects of Haloperidol, Amisulpride, and Quetiapine on Bone Turnover Markers in Patients With Schizophrenia.
    Liang Y; Su YA; Zhao ZG; Gao N; Huang JZ; Tang MQ; Li KQ; Yang FD; Yu X; Si TM
    J Clin Psychopharmacol; 2015 Oct; 35(5):583-6. PubMed ID: 26270200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
    Robinson DG; Gallego JA; John M; Petrides G; Hassoun Y; Zhang JP; Lopez L; Braga RJ; Sevy SM; Addington J; Kellner CH; Tohen M; Naraine M; Bennett N; Greenberg J; Lencz T; Correll CU; Kane JM; Malhotra AK
    Schizophr Bull; 2015 Nov; 41(6):1227-36. PubMed ID: 26338693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis.
    Labad J; Montalvo I; González-Rodríguez A; García-Rizo C; Crespo-Facorro B; Monreal JA; Palao D
    Schizophr Res; 2020 Aug; 222():88-96. PubMed ID: 32507371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.
    Takase M; Kanahara N; Oda Y; Kimura H; Watanabe H; Iyo M
    J Psychopharmacol; 2015 Apr; 29(4):383-9. PubMed ID: 25735995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.